Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - X4 Pharmaceuticals, Inc | asns-ex322_469.htm |
| EX-31.2 - EX-31.2 - X4 Pharmaceuticals, Inc | asns-ex312_467.htm |
| EX-31.1 - EX-31.1 - X4 Pharmaceuticals, Inc | asns-ex311_468.htm |
| EX-23.1 - EX-23.1 - X4 Pharmaceuticals, Inc | asns-ex231_447.htm |
| EX-10.37 - EX-10.37 - X4 Pharmaceuticals, Inc | asns-ex1037_392.htm |
| 10-K - 10-K - X4 Pharmaceuticals, Inc | asns-10k_20171231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Arsanis, Inc. (the “Company”) for the year ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, René Russo, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge on the date hereof:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: March 9, 2018 |
/s/ René Russo |
|
|
René Russo President and Chief Executive Officer (principal executive officer) |